Paper Details

  1. Home
  2. Paper Details

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.

Author: El-AminH, El-KhayatH, FouadY, KamalE M, MaherM, MohamedH I, RiskA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study found that the SOF/DCV combination therapy has proven efficacy and safety in treating patients with hepatitis C-related liver cirrhosis genotype 4.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials. AIM: To investigate the efficacy and safety of SOF/DCV for treatment of patients with hepatitis C-related liver cirrhosis genotype 4. METHODS: Multic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/apt.14482

データ提供：米国国立医学図書館（NLM）

A Hopeful Oasis in the Desert of Hepatitis C Treatment

The field of [hepatitis C treatment] is like a vast desert, where the search for effective and safe treatments has long been a challenge. This study investigates the efficacy and safety of a combination therapy, [SOF/DCV], in patients with [hepatitis C-related liver cirrhosis genotype 4]. The researchers embarked on a [multicenter study] involving 551 patients, including both treatment-naive and treatment-experienced individuals.

A Promising New Direction: High Sustained Virological Response Rates

The results, like a well-stocked oasis, offer a glimmer of hope. The study found high [sustained virological response (SVR12)] rates in both treatment-naive and treatment-experienced patients, suggesting that SOF/DCV could be a valuable tool for combating hepatitis C-related liver cirrhosis genotype 4.

Navigating the Desert: Managing Side Effects

While the study reveals the potential of SOF/DCV, it also underscores the need to carefully navigate the desert of potential side effects. The most common side effects included [anemia], [fatigue], [headache], and [pruritus], while more serious side effects, including [HCC] and [hepatic encephalopathy], were observed mainly in patients with advanced cirrhosis.

Dr. Camel's Conclusion

This study offers a beacon of hope in the desert of hepatitis C treatment. The combination therapy, SOF/DCV, demonstrates promising efficacy and safety in treating patients with hepatitis C-related liver cirrhosis genotype 4. While side effects must be carefully monitored, this research represents a significant step forward in managing this challenging disease.

Date :
  1. Date Completed 2019-03-12
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29314146

DOI: Digital Object Identifier

10.1111/apt.14482

Related Literature

Article Analysis
・Side Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.